Inflammaging
Inflammaging names the slow, sterile, systemic rise in inflammatory tone that accumulates with age and predicts disease before any single test shows a diagnosis.
Also known as: inflamm-aging, chronic low-grade systemic inflammation, sterile inflammation of aging
The name comes from a 2000 paper in Annals of the New York Academy of Sciences by Claudio Franceschi and colleagues at the University of Bologna. Tracking Italian centenarians and their offspring, they found that the people who reached very old age were not the ones with the lowest inflammatory load, but the ones whose inflammatory and anti-inflammatory signaling stayed in balance. They coined inflammaging for the underlying state: a chronic, low-grade, sterile inflammatory tone, present without acute infection or autoimmune disease, that rises with age and tracks risk for most major age-related conditions. Twenty-five years on, the word has crossed from geroscience journals into clinic intake forms and direct-to-consumer test menus, and the field now builds biomarker panels that try to measure it directly.
What It Is
Inflammaging isn’t a disease and isn’t a single molecule. It is a state of the whole inflammatory system in which production of pro-inflammatory cytokines, acute-phase proteins, and complement components is mildly but persistently elevated, anti-inflammatory regulation is incomplete, and the system can no longer return to baseline as cleanly as it did at twenty-five. The label is descriptive, not diagnostic.
Several upstream sources feed the state. Senescent cells accumulate in tissues and secrete the senescence-associated secretory phenotype, a cocktail of cytokines, chemokines, proteases, and growth factors that signals to neighbors and recruits immune cells. The aging gut barrier becomes more permeable to bacterial fragments such as lipopolysaccharide; these reach the systemic circulation as a low-level antigenic load. Decades of viral exposure leave the adaptive immune system with expanded memory pools that release cytokines on stimulation more readily than they did in youth. Damaged mitochondria spill fragments of mitochondrial DNA that the innate immune system reads as foreign. Visceral adipose tissue grows and recruits inflammatory macrophages. Several of these processes are themselves named hallmarks of aging, and inflammaging is the integrative signal where most of them converge.
The most-used clinic readouts that approximate the state are old and cheap: high-sensitivity C-reactive protein (hsCRP), interleukin-6 (IL-6), ferritin, and fibrinogen. None was designed for chronic-aging questions; they were designed for acute-inflammation, infection, and cardiovascular-risk screening, and they integrate too much short-term noise to be ideal trend markers of slow aging biology. A newer biomarker class profiles the sugar groups attached to circulating antibodies (IgG N-glycan profiling) and converts the shape of the immunoglobulin glycome into a composite age-associated score; commercial platforms (GlycanAge and successors) sell this readout direct-to-consumer and have begun appearing in clinic protocols and a small number of hospital integrations. Other emerging readouts include cell-free mitochondrial DNA and machine-learned proteomic clocks built on inflammatory panels.
The concept is real, well-supported in mechanism and cohort data, and linked to most major age-related diseases. The question for any specific test is narrower: how well does this measure track the underlying state rather than acute illness or transient noise, and what clinical decision does it change? Most of the time, that decision doesn’t turn on a new biomarker.
Acute inflammation is a normal, helpful response to injury and infection that resolves within hours to days. Inflammaging is what happens when the baseline, between any acute event, drifts upward over decades. The two are produced by overlapping but distinct biology and respond to different things. An acutely elevated CRP after a viral infection is not an inflammaging measurement; the same person’s average CRP across a year of healthy weeks may be.
Why It Matters
A reader landing on this concept usually does so for one of three reasons. First, an extended-bloodwork panel returned an elevated hsCRP or IL-6 without an obvious infection, and a clinic blog post used the word inflammaging without defining it. Second, the reader paid for a direct-to-consumer IgG-glycan test and got back a composite “glycan age” that they cannot place against the rest of their lab work. Third, they have read enough longevity material — Attia, Patrick, the Outlive successor literature, Fountain Life intake material — that the term has appeared often enough to be worth pinning down.
Each of those entry points carries a specific failure mode. The hsCRP entry point invites confusion between acute and chronic inflammatory signal: a person with a moderate viral illness three weeks before the draw may see a result that has nothing to do with their aging biology. The glycan-test entry point invites the assumption that a single composite score is the verdict on the system, which it isn’t. The longevity-reading entry point invites a different error: treating inflammaging as a knob to turn rather than as the readout of upstream biology that other interventions affect indirectly.
A reader who can place the term properly gets a working map across the rest of the field. The chronic-inflammation hallmark in the aging hallmarks framework, the cellular-senescence pathway that senolytic cocktails target, the immune-aging signals reported in urolithin A trials, the complement-pathway shifts in the caloric restriction CALERIE follow-up, the hearing correction literature on auditory-deprivation neuroinflammation, and the dietary work on Mediterranean diet and exercise-induced hormesis all touch the same integrative state. Holding the name lets a reader follow one story across a dozen interventions instead of re-deriving the link each time.
How to Recognize It
Inflammaging is recognized as a sustained, low-grade signal across the cheap inflammation panel, in the absence of an acute trigger. The operational reading takes three layers.
| Layer | Question | Failure if skipped |
|---|---|---|
| Acute vs chronic | Is there an infection, injury, dental abscess, vaccination, recent illness, or autoimmune flare within the last three to four weeks? | A single elevated result is read as aging biology when it is acute biology |
| Baseline pattern | Across two or three measurements at least a month apart, is the signal persistently above the cohort age-matched range? | A noisy proxy becomes a verdict; intra-person variability is ignored |
| Confound load | Are obesity, smoking, sedentary behavior, untreated sleep apnea, periodontal disease, chronic kidney disease, or polypharmacy plausibly carrying most of the signal? | The chronic-aging story is told for a state that a treatable upstream condition explains |
The cheap panel, repeated calmly, does most of the work. A baseline hsCRP under roughly 1.0 mg/L in the absence of acute illness sits in the favorable end of the age-adjusted range; values persistently above 3.0 mg/L in an otherwise stable adult are associated with elevated cardiovascular and all-cause risk in large prospective cohorts and are worth a clinical conversation rather than a supplement plan. IL-6 reference ranges are assay-dependent and harder to read at home; values consistently in the upper reference range, paired with elevated hsCRP, strengthen the signal that the inflammatory floor has risen. Ferritin and fibrinogen are useful confound checks — high ferritin in the presence of iron overload, hemochromatosis, or chronic liver disease can drive an inflammatory pattern that has its own treatment path.
The IgG-glycan-based tests add a different angle. The IgG glycome shifts with age in a stereotyped direction (galactosylation and sialylation fall, core fucosylation and bisecting GlcNAc rise), producing antibodies whose Fc-region effector function biases pro-inflammatory. Commercial platforms convert these compositional shifts into a composite age-like score. The reading rule is the same as for any composite: the score is a trend marker tied to the platform’s training set, not a stand-alone diagnosis. A score above chronological age is worth investigating in the standard inflammation and cardiometabolic panels before any further action; a score below chronological age does not retire the rest of the risk map.
A single hsCRP, IL-6, ferritin, or glycan-age value is not an inflammaging diagnosis. The state is defined by persistence across time, in the absence of acute drivers, against an age-adjusted baseline. Reading one number once and adjusting a plan around it is the single-biomarker tunnel error applied to a slow-moving target.
How It Plays Out
A 54-year-old runs an extended panel that includes hsCRP and IL-6. The hsCRP returns at 4.2 mg/L; IL-6 is in the upper reference range. She had a respiratory infection three weeks earlier and noticed lingering fatigue. The clinician orders a repeat at six weeks. The hsCRP returns at 0.9 mg/L; IL-6 has fallen back to mid-range. The first reading was acute biology with an inflammaging-style signature, not the chronic-state signal it appeared to be. The repeat tells the truth.
A 61-year-old purchases a direct-to-consumer IgG-glycan test after seeing it featured in a podcast. The result reports a “glycan age” 7 years above chronological age. The composite was driven mostly by lower galactosylation and higher bisecting GlcNAc. His standard panel shows persistent hsCRP at 3.1 mg/L over two draws and an elevated waist-to-height ratio. The clinical conversation does not turn on the glycan score; it turns on the persistent hsCRP, the visceral-adiposity finding, an undiagnosed sleep-apnea suspicion, and a dietary pattern that has drifted toward ultra-processed convenience food. The standard, cheap markers were already telling the same story the glycan composite did, and the actionable interventions sit upstream of any biomarker.
A clinic stacks hsCRP, IL-6, ferritin, fibrinogen, IgG-glycan profiling, and a proteomic inflammatory clock into a premium quarterly screen, then bundles the readouts into a composite “inflammaging score” that becomes the organizing target of the patient’s annual plan. Supplement choices, dietary interventions, and clinical decisions all reference the composite. Blood pressure, sleep quality, training adherence, alcohol intake, and family disease history get less attention than the score moves. Walking out with a recommended supplement stack to “lower inflammaging” is the biomarker treadmill in action: the score moves; the risk map may or may not move with it.
Consequences
Benefits. A reader who has the word can ask a clinician about chronic inflammatory tone without sliding into vague wellness talk, can interpret an elevated hsCRP against the right reference frame, and can connect the chronic-inflammation hallmark, the cellular-senescence pathway, gut-barrier biology, and the immune-aging literature without re-deriving the link each time. The cheap standard panel does most of the work it needs to. hsCRP, IL-6, ferritin, and fibrinogen carry decades of large-cohort evidence linking persistent elevation to cardiovascular events, frailty, sarcopenia, infection susceptibility, dementia risk, and all-cause mortality, and they sit on routine bloodwork at low cost. Understanding inflammaging lets a reader use that signal calmly rather than panicking at one result or dismissing it as “just inflammation.”
Liabilities. The concept invites two failure modes. The first is treating inflammaging as a directly targetable variable. No intervention has been shown to lower a composite inflammaging score and, in a controlled human trial, reduce a clinical event. Diet, exercise, weight loss, sleep, and treatment of upstream conditions all lower hsCRP and IL-6 in observational and intervention studies, but those interventions work for their own demonstrated reasons and the inflammatory readout reflects the change rather than driving it. Reading the score as a knob inverts the causal arrow.
The second failure mode is biomarker proliferation. Adding an IgG-glycan composite, cell-free mitochondrial DNA, a proteomic clock, and an inflammatory score panel to an already-loaded annual screen costs hundreds to thousands of dollars and produces outputs that don’t yet change the clinical decision in most adults. The cheaper standard panel, repeated and read in context, captures most of the actionable signal. The emerging tests have research value and may earn clinical value in time; the reader doesn’t need to be on the leading edge of paying for them.
The honest evidence summary: the construct is well-supported; persistent elevation of standard inflammation markers in healthy-appearing adults predicts disease and mortality at the population level; no current intervention lowers the construct and, in a randomized trial, demonstrably improves a hard clinical endpoint by virtue of doing so. Treat inflammation as a confirmation marker for the lifestyle and clinical work whose evidence base is already established, and read individual results across time rather than as one-shot verdicts.
Direct-to-consumer marketing routinely treats an inflammaging-style score as if a lower number were the same as longer healthspan. It isn’t. A score is a trend marker; the trial evidence that moving the score moves the outcome remains preliminary. Spend the budget on the interventions whose evidence base already exists (sleep, exercise, diet quality, weight management, treatment of upstream conditions) before paying for the next composite test.
Related Articles
Sources
- Franceschi, Claudio, Massimiliano Bonafè, Silvana Valensin, Fabiola Olivieri, Maria De Luca, Enzo Ottaviani, and Giovanna De Benedictis. “Inflamm-aging: An Evolutionary Perspective on Immunosenescence.” Annals of the New York Academy of Sciences 908 (2000): 244-254. https://doi.org/10.1111/j.1749-6632.2000.tb06651.x
- Franceschi, Claudio, Paolo Garagnani, Paolo Parini, Cristina Giuliani, and Aurelia Santoro. “Inflammaging: A New Immune-Metabolic Viewpoint for Age-Related Diseases.” Nature Reviews Endocrinology 14, no. 10 (2018): 576-590. https://doi.org/10.1038/s41574-018-0059-4
- Furman, David, Judith Campisi, Eric Verdin, Pedro Carrera-Bastos, Sasha Targ, Claudio Franceschi, Luigi Ferrucci, et al. “Chronic Inflammation in the Etiology of Disease across the Life Span.” Nature Medicine 25, no. 12 (2019): 1822-1832. https://doi.org/10.1038/s41591-019-0675-0
- Krištić, Jasminka, Frano Vučković, Cristina Menni, Lucija Mužinić, Tamara Šoić, Toma Keser, Najda Rudan Bišanin, et al. “Glycans Are a Novel Biomarker of Chronological and Biological Ages.” The Journals of Gerontology: Series A 69, no. 7 (2014): 779-789. https://doi.org/10.1093/gerona/glt190
- Štambuk, Jerko, Frano Vučković, Olga Habazin, Marija Hanić, Maja Pučić-Baković, Mirna Šimurina, Najda Rudan Bišanin, et al. “High-Throughput N-Glycan Analysis in Aging and Inflammaging: State of the Art and Future Directions.” Seminars in Immunology 75 (2024): 101890. https://doi.org/10.1016/j.smim.2024.101890
- Ridker, Paul M., Christopher P. Cannon, David Morrow, Nader Rifai, Lynda M. Rose, Carolyn H. McCabe, Marc A. Pfeffer, and Eugene Braunwald. “C-Reactive Protein Levels and Outcomes after Statin Therapy.” New England Journal of Medicine 352, no. 1 (2005): 20-28. https://doi.org/10.1056/NEJMoa042378
- Ferrucci, Luigi, and Elisa Fabbri. “Inflammageing: Chronic Inflammation in Ageing, Cardiovascular Disease, and Frailty.” Nature Reviews Cardiology 15, no. 9 (2018): 505-522. https://doi.org/10.1038/s41569-018-0064-2
- Calçada, Daniela, Daniela Vianello, Eugenia Giampieri, Cristina Sala, Gastone Castellani, Albert de Graaf, Ben van Ommen, et al. “The Role of Low-Grade Inflammation and Metabolic Flexibility in Aging and Nutritional Modulation thereof: A Systems Biology Approach.” Mechanisms of Ageing and Development 136-137 (2014): 138-147. https://doi.org/10.1016/j.mad.2014.01.004
Medical and Legal Boundary
This entry is a reference, not medical advice. It describes a biological construct, the standard inflammation markers used to approximate it, and an emerging class of biomarker tests. It does not diagnose, prescribe, or replace a clinician’s judgment for a specific person.
Persistent elevation of high-sensitivity C-reactive protein, interleukin-6, ferritin, or fibrinogen should be interpreted by a qualified clinician in the context of the rest of the panel, recent illness, medications, and personal history. Do not start, stop, or combine supplements, medications, fasting protocols, or other clinical interventions on the basis of a single inflammatory marker or a single composite biomarker score. Glycan-based and proteomic-clock tests are research-grade or direct-to-consumer commercial products in most jurisdictions and are not approved as diagnostic tests for any longevity indication; their results should be discussed with a clinician before any clinical decision is based on them.